The current fervor for GLP-1RAs in the capital markets as well as in the general public, especially in terms of weight reduction, is probably going to result in overuse, said Chun-Su Yuan, MD, PhD, the Cyrus Tang Professor of Anesthesia and Critical Care at the University of Chicago
Efficacy comparison: brand trial data and real-world expectations Brand Zepbound benchmark data: SURMOUNT-1 (Jastreboff 2022): 22.5% mean weight loss at 72 weeks with 15 mg max dose SURMOUNT-5 (Aronne 2025): 20.2% mean weight loss at 72 weeks with 15 mg max dose, head-to-head vs Wegovy Real-world studies in 2025: typically 14-18% at 12 months Compounded tirzepatide outcomes (when properly dosed): Should approximately match brand data because the molecule is identical Real-world adherence may differ from brand pen users (vials can be harder for needle-averse patients) Dose accuracy depends on syringe technique Quality of API and finished product depends on the pharmacy No published trial has directly compared compounded tirzepatide to brand Zepbound
To continue reading, become a Patently-O member
Ghosh, P., Fontanella, R
The doses were chosen based on semaglutide alcohol intake studies (Marty et al
Cyanocobalamin vs methylcobalamin in compounded formulations Most compounding pharmacies use cyanocobalamin, the synthetic form of B12
